Journal of glaucoma · 2025
One-Year Outcomes of Hydrus Microstent Combined With Cataract Surgery: Efficacy Across Glaucoma Severity Levels.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bachour Kenan, Dahoud Andrea, Berkache Moncef, Chow Daniel R, Yuan Po Hsiang Shawn, Durr Georges
Аннотация
PRÉCIS: The Hydrus Microstent combined cataract surgery reduces IOP and medication use in mild-to-moderate glaucoma. For severe open angle glaucoma, it reduces medication use while maintaining a favorable safety profile.
PURPOSE: This study evaluates the 12-month clinical outcomes of Hydrus Microstent combined with cataract surgery in eyes with open angle glaucoma stratified by disease severity.
MATERIALS AND METHODS: Retrospective, single-surgeon cohort study. Eyes with mild-to-moderate and severe glaucoma undergoing Hydrus implantation combined with cataract surgery were included. Primary outcomes were complete (no medication) and qualified (with medication) success (6-21 mm Hg) at 1 year. Secondary outcomes included IOP, number of glaucoma medications, complications, failure, and success rates for 6-18 and 6-15 mm Hg IOP thresholds.
RESULTS: A total of 147 eyes from 100 patients with a median baseline IOP of 16.0 [IQR: 14.0-20.0] on 2.0 [1.0-3.0] medications were included. Complete success was achieved in 78% and qualified success in 93% of eyes, with mild-to-moderate glaucoma achieving 77% and 92%, and severe glaucoma achieving 84% and 96%, respectively. In the mild-to-moderate group, mean IOP decreased from 17.1±3.8 mm Hg (SD) to 15.5±2.7 mm Hg ( P <0.0003), and medications were reduced from 2.2±1.1 to 0.6±1.1 ( P <0.0001). In the severe group, mean IOP was not significantly changed, and medications were reduced from 2.6±1.3 to 1.2±1.3 ( P =0.0008). At 12 months, 64% of eyes were medication-free, and 67% of severe cases required one or fewer medications. Focal peripheral anterior synechiae (35%) was the most common complication.
CONCLUSION: The Hydrus Microstent lowered medication use across all glaucoma severities. Further studies with larger sample sizes are warranted to support these findings.
PURPOSE: This study evaluates the 12-month clinical outcomes of Hydrus Microstent combined with cataract surgery in eyes with open angle glaucoma stratified by disease severity.
MATERIALS AND METHODS: Retrospective, single-surgeon cohort study. Eyes with mild-to-moderate and severe glaucoma undergoing Hydrus implantation combined with cataract surgery were included. Primary outcomes were complete (no medication) and qualified (with medication) success (6-21 mm Hg) at 1 year. Secondary outcomes included IOP, number of glaucoma medications, complications, failure, and success rates for 6-18 and 6-15 mm Hg IOP thresholds.
RESULTS: A total of 147 eyes from 100 patients with a median baseline IOP of 16.0 [IQR: 14.0-20.0] on 2.0 [1.0-3.0] medications were included. Complete success was achieved in 78% and qualified success in 93% of eyes, with mild-to-moderate glaucoma achieving 77% and 92%, and severe glaucoma achieving 84% and 96%, respectively. In the mild-to-moderate group, mean IOP decreased from 17.1±3.8 mm Hg (SD) to 15.5±2.7 mm Hg ( P <0.0003), and medications were reduced from 2.2±1.1 to 0.6±1.1 ( P <0.0001). In the severe group, mean IOP was not significantly changed, and medications were reduced from 2.6±1.3 to 1.2±1.3 ( P =0.0008). At 12 months, 64% of eyes were medication-free, and 67% of severe cases required one or fewer medications. Focal peripheral anterior synechiae (35%) was the most common complication.
CONCLUSION: The Hydrus Microstent lowered medication use across all glaucoma severities. Further studies with larger sample sizes are warranted to support these findings.